

Differences in the Prevalence and Characteristics of Metabolic Syndrome in Rheumatoid Arthritis and Osteoarthritis: a Multicentric Study

Šalamon, Lea; Morović Vergles, Jadranka; Marasović Krstulović, Daniela; Kehler, Tatjana; Šakić, Davorin; Badovinac, Olga; Vlak, Tonko; Novak, Srđan; Štiglić Rogoznica, Nives; Hanih, Marino; ...

Source / Izvornik: **Rheumatology International**, 2015, 35, 2047 - 2057

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.1007/s00296-015-3307-0>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:239:951547>

Rights / Prava: [Attribution 4.0 International](#) / [Imenovanje 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-11-22**



Repository / Repozitorij:

[Repository UHC Osijek - Repository University Hospital Centre Osijek](#)

Differences in the prevalence and characteristics of metabolic syndrome in rheumatoid arthritis and osteoarthritis: a multicentric study

Lea Šalamon¹ · Jadranka Morović-Vergles¹ · Daniela Marasović-Krstulović² · Tatjana Kehler³ · Davorin Šakić⁴ · Olga Badovinac⁴ · Tonko Vlak⁵ · Srđan Novak⁶ · Nives Štiglic-Rogoznica⁷ · Marino Hanih⁸ · Dražen Bedeković⁹ · Simeon Grazio¹⁰ · Mira Kadojić¹¹ · Jasminka Milas-Ahić⁹ · Višnja Prus⁹ · Doris Stamenković⁷ · Daniela Šošo⁵ · Branimir Anić¹² · Đurđica Babić-Naglić¹³ · Stjepan Gamulin¹⁴

Received: 13 January 2015 / Accepted: 2 June 2015 / Published online: 10 June 2015
© Springer-Verlag Berlin Heidelberg 2015

Abstract The purpose of the study was to examine whether rheumatoid arthritis (RA) patients have higher prevalence of metabolic syndrome (MetS) than osteoarthritis (OA) patients in association with a higher level of chronic systemic inflammation in rheumatoid arthritis. A total of 583 RA and 344 OA outpatients were analyzed in this multicentric study. Metabolic syndrome was defined using the National Cholesterol Education Program Adult Treatment Panel III criteria. A 1.6-fold higher prevalence of MetS was found in patients with OA compared with the

RA patients. Among the parameters of MetS, patients with OA had significantly higher levels of waist circumference, systolic blood pressure, fasting blood glucose and triglycerides, whereas HDL cholesterol and diastolic blood pressure values were similar in both groups of patients. Higher values of inflammatory markers [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)] in MetS than in non-MetS patients and higher prevalence of MetS in patients with CRP level ≥ 5 mg/L in both RA and OA patients were found. In multivariate logistic regression analysis,

✉ Lea Šalamon
salamonlea@yahoo.com

¹ Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Dubrava University Hospital, University of Zagreb School of Medicine, Av. G. Šuška 6, 10 040 Zagreb, Croatia

² Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Split University Hospital, University of Split School of Medicine, Spinčićeva 1, 21000 Split, Croatia

³ Hospital for Cardiac, Pulmonary and Rheumatic Rehabilitation, Talassotherapy, Ul. Maršala Tita 188, 51410 Opatija, Croatia

⁴ Department of Physical Medicine, Dubrava University Hospital, Av. G. Šuška 6, 10 040 Zagreb, Croatia

⁵ Department of Rehabilitation Medicine and Rheumatology, Split University Hospital, University of Split School of Medicine, Spinčićeva 1, 21000 Split, Croatia

⁶ Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Clinical Hospital Center Rijeka, University of Rijeka School of Medicine, Krešimirova 42, 51000 Rijeka, Croatia

⁷ Department for Rheumatology and Rehabilitation, Clinical Hospital Centre Rijeka, School of Medicine University of Rijeka, Krešimirova 42, 51000 Rijeka, Croatia

⁸ Department of Rheumatic Diseases, Physical Medicine and Rehabilitation, GH “Dr. Josip Benčević”, Andrije Štampara 42, 35000 Slavonski Brod, Croatia

⁹ Department of Internal Medicine, Osijek University Hospital, Josipa Huttlera 4, 31000 Osijek, Croatia

¹⁰ Department of Rheumatology, Physical and Rehabilitation, Medicine, “Sisters of Charity” Clinical Hospital Center, Referral Center for Spondyloarthropathies, Ministry of Health and Social Welfare, Vinogradska Cesta 29, 10000 Zagreb, Croatia

¹¹ Department of Physical Medicine and Rehabilitation, Osijek University Hospital, Josipa Huttlera 4, 31000 Osijek, Croatia

¹² Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb Clinical Hospital Center, University of Zagreb School of Medicine, Kišpatičeva 12, 10000 Zagreb, Croatia

¹³ Department of Rheumatology and Rehabilitation, Zagreb Clinical Hospital Center, University of Zagreb School of Medicine, Kišpatičeva 12, 10000 Zagreb, Croatia

¹⁴ Department of Pathophysiology, University of Zagreb School of Medicine, Šalata 3, 10000 Zagreb, Croatia

significant predictors of MetS were type of arthritis (OA vs. RA; OR 2.5 [95 % CI 1.82–3.43]), age (OR 1.04 [95 % CI 1.03–1.06]) and ESR (OR 1.01; [95 % CI 1.00–1.01]). The significant association between OA and MetS was maintained in the regression model that controlled for body mass index (OR 1.87 [95 % CI 1.34–2.61]). The present analysis suggests that OA is associated with an increased risk of MetS, which may be due to a common underlying pathogenic mechanism.

Keywords Rheumatoid arthritis · Osteoarthritis · Metabolic syndrome · Inflammation

Introduction

The risk of cardiovascular (CV) events and mortality is increased in rheumatoid arthritis (RA) and seems to be approximately 50 % higher in RA patients compared with the general population [1, 2]. The classical cardiovascular risk factors, including smoking, hypertension, dyslipidemia, insulin resistance and diabetes mellitus, obesity and physical inactivity, do not appear to explain the excess cardiovascular risk in RA [3]. A very important link between RA and cardiovascular disease is inflammation as it plays a key role in all stages of atherosclerosis. It also has an influence on and accentuates some of the traditional cardiovascular risk factors, such as dyslipidemia, obesity and insulin resistance [4]. The exact pathophysiologic mechanism by which this relation between cardiovascular disease and RA could be explained is not completely clear.

Metabolic syndrome (MetS) is a cluster of major risk factors for cardiovascular disease such as dyslipidemia, hypertension, insulin resistance, impaired glucose tolerance or diabetes, and obesity. There are multiple criteria for definitions of MetS; the most commonly used are the NCEP/ATP III and International Diabetes Federation criteria [5, 6]. A recent meta-analysis showed that MetS is associated with a twofold increase in cardiovascular outcome and a 1.5-fold increase in all-cause mortality [7]. In addition to insulin resistance, inflammation is closely associated with the pathogenesis of MetS [8].

An increased prevalence of MetS in RA patients was found in a number of studies [9–15], but not in all [16–18]. A 17–45.2 % prevalence of MetS in RA patients was found in the studies with a large number of patients that used the current definitions of MetS [5, 6].

While both have aging and adiposity as important risk factors, osteoarthritis (OA) and the MetS have only recently been associated with one another. In the vast NHANES III study, MetS was prevalent in 59 % of the OA population and 23 % of the population without OA. Each of the five cardiovascular risk factors that comprise MetS was more

prevalent in the OA population [19]. Comparable prevalence of MetS in OA patients (54.9 %) was found in a study by Leite [20]. In the Japanese ROAD study, the risk of knee OA development and progression increased with the presence of each additional component of the MetS [21]. While obesity is a well-recognized risk factor for OA in weight-bearing knee joints, the association of OA with the MetS is not completely explained by an obesity-induced increased biomechanical load. Overweight and obese persons also have an increased risk of OA in hands, which are not weight-bearing, implicating systemic factors in the obesity–OA connection [22]. The pathogenesis of OA and the MetS each involves abnormalities in common metabolic intermediates including glucose, hormones, several growth factors, transcription factors, nitric oxide and reactive oxygen species [23]. Over the last several decades, both OA and the MetS have been increasingly recognized as low-grade inflammatory conditions with elevations in systemic inflammatory markers such as hsCRP (high-sensitivity C-reactive protein) [24]. For both entities, there are clear pathogenic roles for inflammatory mediators and hormones such as IL1 β , TNF α and leptin [23].

Obesity and MetS frequently coexist and define obese individuals “at risk” of adverse health outcomes. Recent studies have identified a subset of obese individuals who have a low burden of adiposity-related metabolic abnormalities compared with “at-risk” obese individuals, the so-called metabolically healthy obese (MHO) phenotype. There is no universally accepted definition of MHO and the extent to which the MHO phenotype is associated with a lower risk of adverse health outcomes remains the subject of debate [25].

There are few studies comparing cardiovascular risk in RA and OA patients. Cardiovascular risk assessment revealed that RA patients exercised more frequently, but they had diabetes more often and their insulin sensitivity and HDL cholesterol concentrations were lower, as compared to OA patients [26]. In another study, prevalence and distribution of known cardiovascular comorbid conditions were similar in RA and OA [27].

The aim of this study was to determine and compare the prevalence of MetS in patients with RA and OA, and to assess the factors associated with MetS. Comparison of the two diseases, both characterized by a chronic course and painful joint involvement, but with either high (RA) or low (OA) levels of chronic systemic inflammation, might reveal the contribution of chronic inflammation on MetS prevalence in these diseases.

Patients and methods

A multicentric cross-sectional study was performed in regional rheumatology medical centers of Croatia. A

total of 625 RA and 352 OA patients who attended the outpatient clinics from September 1 to December 31, 2009, were consecutively enrolled in the study. The presence of MetS was defined according to the updated third report of the NCEP-ATP III criteria by the presence of at least three out of five abnormalities: waist circumference (men > 102 cm, women > 88 cm); triglycerides ≥ 150 mg/dL (1.69 mmol/L) or drug treatment for elevated triglycerides; HDL cholesterol levels (men < 40 mg/dL, 1.03 mmol/L; women < 50 mg/dL, 1.29 mmol/L) or drug treatment for reduced HDL cholesterol; elevated blood pressure (≥ 130 mmHg systolic blood pressure or ≥ 85 mmHg diastolic blood pressure or drug treatment for hypertension); and elevated fasting glucose ≥ 100 mg/dL (5.6 mmol/L) or drug treatment for hyperglycemia [5]. We excluded 42 RA patients and 8 OA patients from the analysis, since they were missing the data necessary for the diagnosis of MetS, which yielded the total of 583 RA and 344 OA patients. The diagnoses of RA and OA (knee, hip and hand) were established by qualified rheumatologists according to the 1987 American College of Rheumatology (ACR) classification criteria for RA [28] and the ACR criteria for OA [29–31]. The study protocol was approved by the Ethical Committee of the Dubrava University Hospital, Zagreb, the coordinative center of the study, and a written informed consent was obtained from all study participants.

All participants underwent a detailed evaluation guided by a questionnaire administered in all collaborative departments. The evaluation included a detailed medical history, physical examination and measurement of body height and weight. Patients with ischemic heart disease were not included in the study. Patients >65 years of age were considered elderly. Body mass index (BMI) was calculated by dividing weight (kg) by height² (square meters), and patients with BMIs >25 were qualified as overweight (including obesity). “Metabolically healthy obese” was defined as patients with BMI ≥ 30 kg/m² and less than three MetS criteria present in OA and RA [25]. Waist and hip circumferences were measured, and the waist-to-hip ratio (WHR) was calculated [32]. Pain and the patients’ general health (GH) were assessed using the appropriate visual analog scales (VAS). Pain VAS (VASP) ranged from 0 to 10, with 10 being the most intensive pain [33]. General health VAS (VASGH) was part of the DAS28-CRP score [34]. VAS was represented by a 100-mm-long line on which the patients evaluated their own health, with 100 mm representing the best health. RA patient functional status and disease activity were assessed by the Croatian translation of the health assessment questionnaire (HAQ) [35] and by the DAS28-CRP score [34].

All antihypertensive and antirheumatic medications taken by the enrolled patients were recorded in detail (indications, dose and duration of treatment). Blood pressure

(BP) was measured after a 5-min rest in a sitting position on the right arm with a mercury sphygmomanometer and a standard cuff. The recorded BP value for each patient was the mean of three subsequent measurements at 5-min intervals. Arterial hypertension (HT) was defined according to the European Society of Hypertension and the European Society of Cardiology 2007 guidelines with BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg [36] or any BP with antihypertensive treatment.

Venous blood samples were collected for laboratory investigations after overnight fasting. The following tests were performed in the laboratories of the collaborative hospitals: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), total cholesterol (Chol), high-density lipoproteins (HDL), low-density lipoproteins (LDL), triglycerides (TG), creatinine and plasma glucose (Glc). When required, oral glucose tolerant tests (OGTT) were performed. Diabetes (DM) was defined by a history of DM with current use of antidiabetic medication or fasting Glc >126 mg/dL (7 mmol/L) or Glc in OGTT (2 h) >200 mg/dL (11.1 mmol/L) [37]. The same standard methods were used in all laboratories, and biochemical assays were performed using Olympus autoanalyzers according to the manufacturer’s protocol.

Statistical analysis

The distribution of data was assessed for normality using Kolmogorov–Smirnov test. Values are presented as median [interquartile range (IQR)], mean [standard deviation (SD)] or percentage [confidence interval (CI)], as appropriate. Comparisons were performed using *t* test, Mann–Whitney *U* test and Chi-square test, for normally distributed, non-normally distributed and categorical variables, respectively. Binary logistic regression was used to assess the association of various variables with MetS in RA and OA patients, as well as in the entire group. In multivariate models, the variables that were significant at $p < 0.2$ level in both groups were included, and a multivariate backward-stepwise analysis was performed also with the inclusion of BMI as a continuous covariate. *p* values <0.05 (two tailed) were considered significant. All statistical analyses were performed using SPSS 17.0 software (SPSS Inc., Chicago, USA). The adjustment of MetS prevalence for age and BMI was made according to [38].

Results

Characteristics of RA and OA patients (Table 1)

The proportion of female patients was higher than that of men in both the RA and OA groups, in a similar ratio. In comparison with OA patients, patients with RA were

Table 1 Characteristics of RA and OA patients

| | RA (<i>N</i> = 583) | OA (<i>N</i> = 344) | <i>p</i> values |
|--|------------------------|------------------------|-----------------|
| MetS (ATPIII) <i>n</i> [% (95 % CI)] | 251 [43.1 (39.0–47.2)] | 236 [68.6 (63.4–73.5)] | <0.001 |
| Sex female <i>n</i> [% (95 % CI)] | 483 [82.8 (79.5–85.8)] | 287 [83.4 (79.1–87.2)] | 0.819 |
| Age (years) | 59 (52–68) | 67 (58–73) | <0.001 |
| Age ≥65 years <i>n</i> [% (95 % CI)] | 205 [35.2 (31.3–39.2)] | 204 [59.3 (53.9–64.5)] | <0.001 |
| Disease duration (years) | 7 (3–15) | 5 (2–10) | <0.001 |
| BMI | 26.5 (23.8–29.3) | 29.5 (26.1–32.3) | <0.001 |
| BMI ≥25 <i>n</i> [% (95 % CI)] | 377 [64.7 (60.6–68.5)] | 291 [84.6 (80.3–88.2)] | <0.001 |
| Metabolically healthy obese ^a [% (95 % CI)] | 7.4 (5.5–9.8) | 8.4 (5.9–11.9) | 0.65 |
| Waist circumference (cm) | 92 (84–100) | 99 (93–108) | <0.001 |
| Hip circumference (cm) | 103 (98–110) | 110 (103–117) | <0.001 |
| WHR | 0.88 (0.82–0.94) | 0.90 (0.83–0.96) | 0.022 |
| VASP | 50.0 (30.0–70.0) | 50.0 (32.0–70.0) | 0.586 |
| VASGH | 50.0 (28.3–67.5) | 50.0 (30.00–60.00) | 0.594 |
| Systolic blood pressure (mmHg) | 132 (120–145) | 135 (126–145) | 0.046 |
| Diastolic blood pressure (mmHg) | 80 (76–90) | 82 (79–90) | 0.088 |
| Dyslipidemia <i>n</i> [% (95 % CI)] | 237 [40.7 (36.6–44.8)] | 180 [52.3 (46.9–57.7)] | 0.001 |
| DM <i>n</i> [% (95 % CI)] | 60 [10.3 (7.9–13.0)] | 59 [17.2 (13.3–21.6)] | 0.003 |
| Hypertension | 354 [60.7 (56.6–64.7)] | 250 [72.7 (67.6–77.3)] | <0.001 |
| Smoking habit | | | |
| Ex-smokers <i>n</i> [% (95 % CI)] | 129 [22.1 (18.8–25.7)] | 52 [15.1 (11.5–19.3)] | <0.001 |
| Current smokers <i>n</i> [% (95 % CI)] | 128 [22.0 (18.7–25.5)] | 51 [14.8 (11.2–19.0)] | 0.008 |
| Laboratory data | | | |
| ESR | 26 (13–43.3) | 14.5 (9–23) | <0.001 |
| CRP (mg/L) | 8.3 (3.1–21) | 2.1 (1.2–3.7) | <0.001 |
| Chol (mmol/L) | 5.5 (4.8–6.3) | 5.7 (4.8–6.5) | 0.085 |
| TG (mmol/L) | 1.3 (1.0–1.9) | 1.7 (1.2–2.2) | <0.001 |
| HDL (mmol/L) | 1.4 (1.2–1.8) | 1.4 (1.2–1.7) | 0.760 |
| LDL (mmol/L) | 3.3 (2.8–4.0) | 3.2 (2.4–3.9) | 0.050 |
| Glc (mmol/L) | 4.9 (4.5–5.5) | 5.5 (4.9–6.0) | <0.001 |
| Creatinine (μmol/L) | 76 (66–86) | 78 (68–89) | 0.152 |

Results are expressed as percentages (95 % CI) or median values (interquartile range) as appropriate

RA rheumatoid arthritis, OA osteoarthritis, MetS metabolic syndrome, CI confidence interval, BMI body mass index, WHR waist-to-hip ratio, VASP pain visual analog scale, VASGH general health visual analog scale, DM diabetes mellitus, ESR erythrocyte sedimentation rate, CRP C-reactive protein, Chol plasma cholesterol, TG plasma triglycerides, HDL high-density lipoprotein, LDL low-density lipoprotein, Glc plasma glucose

^a Participants with BMI ≥30 kg/m² and <3 criteria for MetS

younger, with a lower proportion of elderly patients, had a longer duration of the disease, a higher proportion of smokers (ever and current), a lower BMI and WHR, a lower proportion of overweight/obese patients, similar VASP and VASGH, lower proportion of dyslipidemic patients and a lower proportion of persons with diabetes and hypertension. Laboratory investigations showed higher plasma CRP concentrations and ESR in patients with RA, whereas total Chol, LDL and plasma creatinine concentrations were similar in both groups of patients.

Among the parameters of MetS, in comparison with RA patients, patients with OA had significantly higher levels of

waist circumference, systolic blood pressure, fasting blood glucose and TG, whereas HDL and diastolic blood pressure values were similar in both groups of patients. Analyzing the frequency of “metabolically healthy obese” patients in OA and RA subgroups, we observed no statistically significant difference (8.4 vs. 7.4 %; *p* = 0.65).

Prevalence of MetS in RA and OA patients (Tables 2, 3)

The prevalence of MetS was lower in the RA group than in the OA group and remained lower after adjusting for age

Table 2 Prevalence of metabolic syndrome in RA and OA patients according to risk factors

| | | Proportion of MetS positive patients—% (95 % CI) | | <i>p</i> value |
|----|--|--|----------------------|----------------|
| | | RA (<i>N</i> = 583) | OA (<i>N</i> = 344) | |
| 1 | All patients | 43.1 (39.0–47.2) | 68.6 (63.4–73.5) | <0.001 |
| | All patients—adjusted for age and BMI | 59.3 (55.3–63.3) | 68.6 (63.7–73.5) | 0.005 |
| 2 | Male patients | 40.0 (30.3–50.3) | 70.2 (56.6–81.6) | <0.001 |
| 3 | Female patients | 43.7 (39.2–48.2) | 68.3 (62.6–73.6) | <0.001 |
| | <i>p</i> value 2 versus 3 | 0.498 | 0.778 | |
| 4 | Age <65 years | 36.9 (32.0–42.0) | 60.7 (52.1–68.9) | <0.001 |
| 5 | Age ≥65 years | 54.1 (47.1–61.1) | 74.0 (67.4–79.9) | <0.001 |
| | <i>p</i> value 4 versus 5 | <0.001 | 0.01 | |
| 6 | BMI <25 kg/m ² | 19.6 (14.4–25.7) | 38.5 (25.3–53.0) | 0.004 |
| 7 | BMI ≥25 kg/m ² | 56.0 (50.8–61.0) | 73.9 (68.4–78.8) | <0.001 |
| | <i>p</i> value 6 versus 7 | <0.001 | <0.001 | |
| 8 | Age <65 years, BMI <25 kg/m ² | 12.0 (7.5–18.4) | 23.1 (10.7–42.4) | 0.130 |
| 9 | Age <65 years, BMI ≥25 kg/m ² | 52.6 (46.2–58.9) | 69.3 (60.3–77.0) | 0.003 |
| | <i>p</i> value 8 versus 9 | <0.001 | <0.001 | |
| 10 | Age ≥65 years, BMI <25 kg/m ² | 37.1 (26.1–49.6) | 53.8 (35.5–71.3) | 0.146 |
| 11 | Age ≥65 years, BMI ≥25 kg/m ² | 61.5 (53.4–69.1) | 76.8 (70.1–82.5) | 0.003 |
| | <i>p</i> value 10 versus 11 | 0.001 | 0.013 | |
| 12 | Anamnestic dyslipidemia, yes | 54.4 (47.9–60.9) | 77.8 (71.0–83.6) | <0.001 |
| 13 | Anamnestic dyslipidemia, no | 35.3 (30.2–40.5) | 58.5 (50.6–66.2) | <0.001 |
| | <i>p</i> value 12 versus 13 | <0.001 | <0.001 | |
| 14 | Anamnestic diabetes, yes | 85.0 (73.4–92.9) | 96.6 (88.3–99.6) | 0.054 |
| 15 | Anamnestic diabetes, no | 38.2 (34.1–42.6) | 62.8 (56.9–68.4) | <0.001 |
| | <i>p</i> value 14 versus 15 | <0.001 | <0.001 | |
| 16 | Current smoker, yes | 37.5 (29.1–46.5) | 68.6 (54.1–80.9) | <0.001 |
| 17 | Ex smoker, yes | 48.1 (39.3–57.0) | 75.0 (61.1–86.0) | <0.001 |
| 18 | Nonsmoker | 43.6 (38.1–49.1) | 67.2 (60.9–73.1) | <0.001 |
| | <i>p</i> value 16 versus 17 versus 18 | 0.225 | 0.548 | |
| 19 | CRP <5.0 mg/L | 34.9 (28.5–41.8) | 64.8 (58.6–70.5) | <0.001 |
| 20 | CRP ≥5.0 mg/L | 46.5 (41.2–51.8) | 80.4 (66.9–90.2) | <0.001 |
| | <i>p</i> value 19 versus 20 | 0.008 | 0.034 | |

Results are expressed as percentages (95 % CI) of prevalence

RA rheumatoid arthritis, OA osteoarthritis, MetS metabolic syndrome, CI confidence interval, BMI body mass index, CRP C-reactive protein

and BMI. The prevalence of MetS was lower in RA group in both males and females, while the difference in prevalence of MetS by sex within the RA and OA groups was not statistically significant.

Within the BMI <25 kg/m² group, the RA group had a lower proportion of participants with MetS and a similar result was found in the BMI ≥25 kg/m² group. RA group also had a lower proportion of MetS patients in both <65 years and ≥65 years groups. However, in patients with BMI <25 kg/m², there was no statistically significant difference in the prevalence of MetS within the <65 and 65 and over age strata, owing to the relatively small sample size in this group.

The lower proportion of MetS in RA group in comparison with OA group was also found in both groups regarding the dyslipidemia status (yes/no), in those with no history of anamnestic diabetes, in all strata of smoking status, and both in the participants with normal and high CRP (cutoff value of 5 mg/L). Participants with dyslipidemia in both RA and OA groups had higher frequency of MetS than those without dyslipidemia, and similar result was found for anamnestic diabetes.

The proportion of MetS patients within the RA and OA groups was not statistically significantly different across the smoking strata (current, ex, never).

Table 3 Prevalence of metabolic syndrome in RA and OA patients according to medication usage

| | | Proportion of MetS positive patients—% (95 % CI) | | <i>p</i> value |
|----|------------------------------------|--|----------------------|----------------|
| | | RA (<i>N</i> = 583) | OA (<i>N</i> = 344) | |
| 1 | NSAID(s) users | 39.6 (34.2–45.3) | 70.2 (63.9–75.8) | <0.001 |
| 2 | NSAID(s) nonusers | 46.6 (40.9–52.3) | 65.5 (56.5–73.6) | <0.001 |
| | <i>p</i> value 21 versus 22 | 0.090 | 0.378 | |
| 3 | Opioids users | N.A. | 61.9 (52.9–70.1) | |
| 4 | Opioids nonusers | N.A. | 72.1 (65.9–77.6) | |
| | <i>p</i> value 23 versus 24 | | 0.052 | |
| 5 | Analgesic (acetaminophen) users | 48.2 (41.4–55.2) | 60.3 (51.2–68.8) | 0.038 |
| 6 | Analgesic (acetaminophen) nonusers | 40.4 (35.6–45.4) | 72.8 (66.7–78.2) | <0.001 |
| | <i>p</i> value 25 versus 26 | 0.072 | 0.019 | |
| 7 | Glucocorticoids users | 43.0 (38.2–48.1) | N.A. | |
| 8 | Glucocorticoids nonusers | 43.1 (36.4–50.0) | N.A. | |
| | <i>p</i> value 27 versus 28 | 0.995 | | |
| 9 | Glucocorticoids duration <3 months | 42.6 (34.4–51.3) | N.A. | |
| 10 | Glucocorticoids duration >3 months | 45.5 (39.0–52.1) | N.A. | |
| | <i>p</i> value 29 versus 30 | 0.609 | | |
| 11 | Methotrexate users | 46.1 (40.5–51.9) | N.A. | |
| 12 | Methotrexate nonusers | 40.1 (34.6–45.7) | N.A. | |
| | <i>p</i> value 31 versus 32 | 0.138 | | |
| 13 | Leflunomide users | 46.1 (35.5–57.1) | N.A. | |
| 14 | Leflunomide nonusers | 42.6 (38.3–46.9) | N.A. | |
| | <i>p</i> value 33 versus 34 | 0.552 | | |
| 15 | Chloroquine users | 37.9 (26.5–50.8) | N.A. | |
| 16 | Chloroquine nonusers | 43.6 (39.4–47.9) | N.A. | |
| | <i>p</i> value 35 versus 36 | 0.406 | | |
| 17 | Sulphasalazine users | 43.9 (36.2–51.0) | N.A. | |
| 18 | Sulphasalazine nonusers | 42.8 (38.2–47.4) | N.A. | |
| | <i>p</i> value 37 versus 38 | 0.806 | | |

Results are expressed as percentages (95 % CI) of prevalence

RA rheumatoid arthritis, OA osteoarthritis, MetS metabolic syndrome, CI confidence interval, NSAID(s) nonsteroid anti-inflammatory drugs, N.A. not applicable

The participants with CRP concentration of ≥ 5 mg/L had higher frequency of MetS in both the RA and OA groups.

Regarding the prevalence of MetS by the classes of drugs given in the treatment of arthritis, there was a statistically significantly higher prevalence of MetS in the OA group, regardless of NSAID or other analgesics consumption. Within the OA group, those patients who were not taking analgesic (acetaminophen) had a higher prevalence of MetS than those who did ($p = 0.019$), while in the RA group, there were no significant differences according to the type of treatment used.

Comparison of risk factors, patients' characteristics and laboratory measurements between RA and OA patients (Table 4)

Within the RA group, participants with MetS were older, had a higher systolic and diastolic blood pressure and

higher BMI and WHR. They also scored higher on the VAS scale, had higher CRP and ESR, higher total Chol, LDL cholesterol and TG as well as lower HDL cholesterol. Their creatinine and blood glucose values were also higher, respectively.

Within the OA group, participants with MetS were older, had a higher systolic and diastolic blood pressure, higher BMI and WHR. They had higher CRP and ESR, higher TG and blood glucose and lower HDL cholesterol.

Participants with MetS and RA in comparison with participants with MetS and OA were younger, had higher disease duration, lower BMI (with no significant difference in WHR), higher CRP and ESR, lower HDL cholesterol, higher LDL cholesterol, lower TG and lower blood glucose. There were no differences both between and within the arthritis subgroups according to the pack-years of smoking.

Table 4 Comparison of risk factors, patients' characteristics and laboratory measurements between RA and OA patients

| | RA (<i>N</i> = 583) | | <i>p</i> value | OA (<i>N</i> = 344) | | <i>p</i> value | <i>p</i> value RAMetS+ versus OAMetS+ |
|--|-------------------------|-------------------------|------------------|-------------------------|-------------------------|------------------|---------------------------------------|
| | MetS+ (<i>N</i> = 251) | MetS- (<i>N</i> = 332) | | MetS+ (<i>N</i> = 236) | MetS- (<i>N</i> = 108) | | |
| Age (years) | 63 (55–69) | 56 (48–67) | <0.001 | 68 (59–74) | 65 (52–72) | 0.005 | <0.001 |
| Disease duration (years) | 8 (3–15) | 6 (2–14) | 0.09 | 5 (2–11) | 4 (2–8) | 0.089 | 0.003 |
| Smoking (pack-years) | 20 (9–32) | 18 (8–30) | 0.794 | 15 (5–26) | 19 (5–33) | 0.836 | 0.725 |
| Systolic blood pressure (mmHg) | 138 (130–150) | 127 (120–139) | <0.001 | 138 (130–147) | 127 (120–136) | <0.001 | 0.318 |
| Diastolic blood pressure (mmHg) | 83 (79–90) | 80 (75–85) | <0.001 | 83 (80–90) | 80 (76–83) | <0.001 | 0.958 |
| BMI (kg/m ²) | 27.6 (25.5–30.6) | 25.1 (22.5–28.0) | <0.001 | 31.0 (27.5–33.7) | 26.8 (24.2–30) | <0.001 | <0.001 |
| Waist circumference (cm) | 98 (90–105) | 86 (77–95) | <0.001 | 103 (97–110) | 93 (83–98) | <0.001 | <0.001 |
| Hip circumference (cm) | 106 (100–112) | 100 (95–107) | <0.001 | 112 (106–119) | 105 (100–113) | <0.001 | <0.001 |
| Waist/hip ratio | 0.91 (0.86–0.98) | 0.86 (0.80–0.91) | <0.001 | 0.92 (0.85–0.98) | 0.86 (0.80–0.90) | <0.001 | 0.455 |
| DAS28 | 4.5 (3.4–5.5) | 4.3 (3.2–5.5) | 0.305 | N.A. | N.A. | N.A. | N.A. |
| HAQ | 1.5 (0.8–2.1) | 1.4 (0.7–2.0) | 0.053 | N.A. | N.A. | N.A. | N.A. |
| VASP | 55 (37–72) | 50 (30–70) | 0.047 | 50 (35–70) | 50 (30–69) | 0.064 | 0.441 |
| VASGH | 50 (25–70) | 50 (30–61) | 0.532 | 50 (36–65) | 40 (30–60) | 0.084 | 0.535 |
| RF | 51 (10–155) | 40 (10–151) | 0.403 | N.A. | N.A. | N.A. | N.A. |
| CRP | 9.3 (4.0–22.4) | 6.7 (2.5–19.7) | 0.004 | 2.3 (1.4–4.3) | 1.6 (1.0–2.7) | <0.001 | <0.001 |
| ESR | 28 (15–45) | 24 (13–42) | 0.011 | 16 (10–24) | 13 (8–19) | 0.011 | <0.001 |
| Total cholesterol (mmol/L) | 5.8 (4.9–6.7) | 5.4 (4.8–6.1) | 0.002 | 5.8 (4.9–6.7) | 5.6 (4.8–6.3) | 0.065 | 0.906 |
| HDL cholesterol (mmol/L) | 1.2 (1.0–1.6) | 1.6 (1.3–1.8) | <0.001 | 1.3 (1.1–1.6) | 1.6 (1.4–1.9) | <0.001 | 0.017 |
| LDL cholesterol (mmol/L) | 3.5 (2.9–4.2) | 3.2 (2.7–3.7) | <0.001 | 3.2 (2.4–3.9) | 3.1 (2.5–3.8) | 0.352 | 0.003 |
| Triglycerides (mmol/L) | 1.8 (1.3–2.2) | 1.2 (0.9–1.4) | <0.001 | 1.9 (1.4–2.4) | 1.3 (1.0–1.6) | <0.001 | 0.008 |
| Creatinine (μmol/L) | 79 (69–88) | 74 (65–85) | 0.004 | 80 (68–91) | 76 (68–86) | 0.147 | 0.853 |
| Blood glucose (mmol/L) | 5.1 (4.7–5.9) | 4.8 (4.4–5.2) | <0.001 | 5.8 (5.1–6.4) | 5.1 (4.8–5.4) | <0.001 | <0.001 |

Results are expressed as median values (interquartile range)

Bold values distinguish the parameters of metabolic syndrome among other parameters

RA rheumatoid arthritis, OA osteoarthritis, MetS metabolic syndrome, BMI body mass index, DAS28 28-joint disease activity score, HAQ Health Assessment Questionnaire, VASP pain visual analog scale, VASGH general health visual analog scale, RF rheumatoid factor, CRP C-reactive protein, ESR erythrocyte sedimentation rate, HDL high-density lipoprotein, LDL low-density lipoprotein

Logistic regression analysis

In univariate logistic regression models done separately for RA and OA groups, significant predictors of MetS were age, duration of disease, BMI and ESR for RA patients, and age and BMI for OA patients. The variables that were significant at $p < 0.2$ level in both groups were included in backward-stepwise multivariate analyses for the entire pool of participants with disease (RA/OA) added as binary variable. Another model was performed by excluding BMI in order to assess the impact of BMI on the association of arthritis type with MetS. The results are shown in Tables 5 and 6. Significant predictors of MetS were OA (in comparison with RA), higher ESR values and older age. The inclusion of BMI in the model (higher BMI being significant predictor of MetS) somewhat diminished the association of the type of arthritis with MetS; however, it remained significant.

Discussion

In this study, prevalence of MetS in RA patients is consistent with reported prevalence [9, 13, 17], whereas the prevalence of MetS in OA patients was somewhat higher than earlier reported prevalence [19, 20]. This difference can be, at least partially, attributed to disparities in the study design, the population studied and the OA criteria used.

A 1.6-fold higher prevalence of MetS was found in the patients with OA compared with the RA patients (68.6 vs. 43.1 %; $p < 0.001$) and remained higher after adjusting for age and BMI (68.6 vs 59.3 %, $p = 0.005$), with higher prevalence in both males and females. The prevalence was higher across the subgroups of age and BMI, with the exception of patients with BMI <25 kg/m² owing to the relatively small sample size in this group. In NHANES III study, the crude prevalence of MetS was >twofold higher

Table 5 Univariate logistic regression analysis with MetS (ATPIII) as dependent variable

| Variable | OR (95 % CI) | <i>p</i> value |
|-----------------------------------|---------------------|----------------|
| RA group (<i>N</i> = 583) | | |
| Gender | 1.164 (0.750–1.804) | 0.498 |
| Age | 1.048 (1.032–1.064) | <0.001 |
| RA duration | 1.018 (1.000–1.035) | 0.05 |
| BMI | 1.138 (1.093–1.184) | <0.001 |
| Glucocorticoids use ever | 1.062 (0.684–1.648) | 0.790 |
| Glucocorticoids use now | 0.947 (0.670–1.338) | 0.757 |
| DAS28 | 1.059 (0.951–1.179) | 0.295 |
| HAQ | 1.017 (0.912–1.135) | 0.756 |
| VASP | 1.006 (0.999–1.013) | 0.080 |
| VASGH | 1.003 (0.995–1.010) | 0.500 |
| RF | 1.000 (0.999–1.000) | 0.551 |
| CRP | 1.006 (0.999–1.013) | 0.070 |
| ESR | 1.009 (1.002–1.016) | 0.017 |
| Smoking now (vs. not smoking now) | 0.745 (0.498–1.114) | 0.152 |
| OA group (<i>N</i> = 344) | | |
| Gender | 0.915 (0.493–1.701) | 0.780 |
| Age | 1.035 (1.013–1.057) | 0.002 |
| OA duration | 1.019 (0.990–1.049) | 0.208 |
| BMI | 1.175 (1.108–1.246) | <0.001 |
| VAS | 1.009 (0.999–1.019) | 0.079 |
| VASGH | 1.011 (0.999–1.024) | 0.078 |
| CRP | 1.035 (0.983–1.091) | 0.191 |
| ESR | 1.018 (0.999–1.038) | 0.061 |
| Smoking now | 1.001 (0.527–1.900) | 0.997 |

RA rheumatoid arthritis, OA osteoarthritis, CI confidence interval, BMI body mass index, DAS28 28-joint disease activity score, HAQ Health Assessment Questionnaire, VASP pain visual analog scale, VASGH general health visual analog scale, RF rheumatoid factor, CRP C-reactive protein, ESR erythrocyte sedimentation rate

in the population with OA compared with control group, regardless of sex, and it was limited to the population ≤ 18 –65 years [19].

Table 6 Multivariate logistic regression analysis with MetS (ATPIII) as dependent variable

| Model without BMI | OR (95 % CI) | <i>p</i> value |
|-------------------|---------------------|----------------|
| Age (years) | 1.044 (1.030–1.057) | ≤ 0.001 |
| ESR | 1.007 (1.000–1.014) | 0.040 |
| OA (vs. RA) | 2.502 (1.824–3.431) | ≤ 0.001 |
| Model with BMI | OR (95 % CI) | <i>p</i> value |
| Age (years) | 1.040 (1.026–1.054) | ≤ 0.001 |
| ESR | 1.010 (1.002–1.017) | 0.010 |
| OA (vs. RA) | 1.866 (1.335–2.609) | ≤ 0.001 |
| BMI | 1.150 (1.110–1.191) | ≤ 0.001 |

MetS metabolic syndrome, ESR erythrocyte sedimentation rate, OA osteoarthritis, RA rheumatoid arthritis, BMI body mass index, CI confidence interval

The overall reported prevalence of MetS in Croatia in persons older than 40 years is 38.7 % [39]. When age was taken into account (we compared our data for the 40–59 and 60+ age groups with the published data) according to 95 % CI, there was no difference in the prevalence of MetS in 40–59 group of patients with RA compared with the prevalence in the general Croatian population (35.8 % [95 % CI 30.3–41.8] vs. 36.2 % [95 % CI 33.7–38.9]), while in the 60+ age group patients with RA, higher prevalence of MetS (53.7 % [95 % CI 47.9–59.4] vs. 41.6 % [95 % CI 38.7–44.5]) could be assumed. In the OA group, prevalence of MetS was higher than in general population both in 40–59 age group (58.3 % [95 % CI 48.3–67.7]) and in 60+ age group (73.4 % [95 % CI 67.5–78.5]). However, this indirect comparison of prevalence is rather insufficient, and investigations with proper control groups are needed.

Among the parameters of MetS, in comparison with RA patients, patients with OA had significantly higher levels of waist circumference, systolic blood pressure, fasting blood glucose and TG, whereas HDL cholesterol and diastolic blood pressure values were similar in both groups of patients. Therefore, four of the six individual cardiovascular risk factors values assessed were significantly higher in patients with OA in comparison with RA patients. In NHANES III study, four (hypertension, abdominal obesity, elevated TG and elevated fasting blood glucose) of the five MetS constituent risk factors were significantly more prevalent in the population with OA than in the general population without OA. Low HDL-C levels were not significantly more prevalent in the population with OA [19].

Significant predictors of MetS were age, duration of disease, BMI and ESR for RA patients, and age and BMI for OA patients. The fact that age was independently associated with the presence of MetS is not surprising because this is a variable known to increase the frequency of comorbidities, MetS among them [14, 17]. However, in NHANES III study, the population with OA at a young age had a substantially increased risk of having MetS relative

to the general population without OA, but as age increased, this relative risk diminished, until age 78 years, at which point the risk of having MetS became equal in the two populations [19]. In a study by Chung et al., the prevalence of MetS was 30 % in RA patients with long-standing disease, 22 % in patients with RA patients with early arthritis and 10 % in controls, respectively [10]. Disease duration was similar in RA patients with and without MetS in some studies [9, 14, 18].

Higher values of inflammatory markers (CRP, ESR) in MetS than in non-MetS patients and higher prevalence of MetS in patients with CRP level >5 mg/L in both RA and OA patients indicate an association of chronic inflammation and MetS. However, the prevalence of MetS in RA patients is lower than in OA patients although the values of inflammatory markers are higher in the former than in the latter. Probably this is due to rather weak association of chronic inflammation and MetS, and the effect of chronic inflammation is overwhelming by other factors, as indicated by regression analyses where association between CRP and MetS was not expressed (Table 5).

Unlike some previous studies [9–11, 13], there was no association between RA disease activity and MetS assessed by the DAS28-CRP (Tables 4, 5). However, Sahebari et al. [17] found no association between DAS 28 and the presence of MetS components by either definition. The association between higher ESR and the presence of MetS in patients with RA in our study was previously reported [11, 15]. These findings further support the role of chronic inflammation in insulin resistance development [40]. However, in two recent studies, no relationship between the MetS and ESR was observed [12, 41].

Logistic regression incorporating the type of arthritis showed that of all variables analyzed, having OA (in comparison with RA) was the most influential predictive factor for having MetS (OR 2.502, 95 % CI 1.824–3.431), with age (OR 1.044, 95 % CI 1.030–1.057) and ESR (OR 1.007, 95 % CI 1.000–1.014). The significant association between OA and MetS was maintained in the regression model that controlled for BMI (Table 6), and the risk of having MetS was also significantly associated with higher ESR values and older age. In NHANES study, having OA was the most influential predictive factor for having MetS [19]. The influence of OA on the probability of having MetS was dependent on age, being more significant at younger ages, unlike in our study.

In some studies, methotrexate therapy was associated with reduced prevalence of MetS in patients with RA [11, 12, 42]. However, these findings are not consistent with other studies [13, 18]. In addition, the use of glucocorticoids did not significantly contribute to the presence of MetS in patients with RA in previous reports (10, 11, 18). Our results showed no significant association of MetS with

NSAID use in RA and OA and no association of MetS with any disease-modifying drug (DMARD) or glucocorticoid use in RA.

The current view is that OA is a group of disease that can be differentiated based on the risk factors involved and mechanisms underlying the joint damage (aging, obesity, genetic factors, or injury). The association between obesity and hand osteoarthritis suggests a role for circulating mediators released by the adipose tissue known as adipokines [22]. Thus, osteoarthritis may have a systemic metabolic component. Converging evidence from epidemiological and biological studies support the concept of metabolic osteoarthritis, defined as a broad clinical phenotype that includes obesity-related osteoarthritis and OA related to hypertension, type 2 diabetes and dyslipidemia [43, 44].

The commonalities in pathogenic mechanism between MetS and OA are supported by epidemiological data. As a result of the finding that having OA at the mean age of the general population is itself associated with a 5.26-fold increased risk of MetS even when controlling for obesity, it has been suggested that the finding of OA, alone, should prompt evaluation for cardiovascular disease [19]. Also, Kornat et al. [45] found an association between popliteal artery wall thickness and generalized OA which persisted even after correction for sex, age and BMI suggesting that OA is a part of MetS and not solely correlated with obesity.

Osteoarthritis may be associated with either MetS or each of its components [43], although published data are somewhat conflicting [44]. In the NHANES III cohort, a 1-point increase in HOMA-IR was associated with an increase in the knee OA risk of 18 % in non-obese males and 34 % in obese males after adjustment on several factors including age [46]. In the ROAD study, glucose intolerance was independently associated with the development and progression of radiographic knee OA [47]. Although independent associations between OA and type 2 diabetes were demonstrated in other populations, negative studies have been reported [48, 49]. An independent association between hypertension and OA has been reported [46]. In our study population, as previously reported, a robust association of age and BMI with HT prevalence in both RA and OA was shown. Higher HT prevalence in OA patients in comparison with RA patients was rather due to age and BMI than due to features of the disease [50].

At present, a prevailing hypothesis regarding MetS is that chronic low-grade inflammation may be responsible, at least in part, for the development of systemic abnormalities such as glucose and lipid dysregulation, hypertension and OA [43].

Several limitations are to be recognized. First, the cross-sectional design can establish association but not causality. Second, the non-inclusion of a healthy control group may weaken the conclusions of the study. Third,

RA inflammation fluctuates, and CRP and DAS28-CRP as a cross-sectional markers may not capture the long-term cumulative inflammatory burden. Fourth, patients with different localizations of OA (knee, hip or hand) were studied as a group, whereas the systemic impact of MetS may depend on the localization of OA. Fifth, the extent of radiographic severity of RA or OA was not analyzed in the study. Finally, we cannot exclude the possibility of patient selection bias in both RA and OA, as most of the centers from which patients were recruited are a secondary care centers.

In conclusion, the present analysis suggests that OA is associated with increased risk of MetS. Cause-and-effect relationship cannot be determined from an analysis of cross-sectional data; our analysis does not suggest that OA leads to MetS or vice versa. However, our findings strongly suggest that common pathogenic mechanism may be active in patients with OA and patients with MetS.

Acknowledgments This work was supported by a grant from the Ministry of Science, Education and Sport, the Republic of Croatia (198-1081874-0183) to Jadranka Morović-Vergles).

Conflict of interest The authors declare no conflicts of interest.

Ethical standard A written informed consent was obtained from all study participants.

References

- Avina-Zubieta J, Choi H, Sadatsafavi M, Etminan M, Esdaile J, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Arthritis Rheum* 59:1690–1697
- Avina-Zubieta J, Thomas J, Sadatsafavi M, Lehman A, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Ann Rheum Dis* 71:1524–1529
- Ku IA, Imboden JB, Hsue PY, Ganz P (2009) Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. *Circ J* 73:977–985
- Liao K, Solomon D (2013) Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. *Rheumatology (Oxford)* 52:45–52
- Grundy SM, Cleeman JJ, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 110:227–239
- Alberti KG, Zimmet P, Shaw J et al (2005) The metabolic syndrome: a new worldwide definition. *Lancet* 366:1059–1062
- Mottillo S, Filion KB, Genest J et al (2010) The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. *J Am Coll Cardiol* 56:1113–1132
- Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. *Circulation* 111:1448–1454
- Da Cunha VR, Brenol CV, Brenol JC, Fuchs SC, Arlindo EM et al (2012) Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. *Scand J Rheumatol* 41:186–191
- Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T et al (2008) Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. *Atherosclerosis* 196:756–763
- Dao HH, Do QT, Sakamoto J (2010) Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study. *Arthritis Res Ther* 12:R218
- Zonana-Nacach A, Santana-Sahagún E, Jiménez-Balderas FJ, Camargo-Coronel A (2008) Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. *J Clin Rheumatol* 14:74–77
- Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertias GK et al (2007) Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. *Ann Rheum Dis* 66:28–33
- Salinas MJ, Bertoli AM, Lema L, Saucedo C, Rosa J, Quintana R et al (2013) Prevalence and correlates of metabolic syndrome in patients with rheumatoid arthritis in Argentina. *J Clin Rheumatol* 19:439–443
- Rostom S, Mengat M, Lahlou R, Hari A, Bahiri R, Hajjaj-Hasouni N (2013) Metabolic syndrome in rheumatoid arthritis: case control study. *BMC Musculoskelet Disord* 14:147
- Karimi M, Mazloomzadeh S, Kafan S, Amirmoghaddami H (2011) The frequency of metabolic syndrome in women with rheumatoid arthritis and in controls. *Int J Rheum Dis* 14:248–254
- Sahebari M, Goshayeshi K, Mirfeizi Z et al (2011) Investigation of the association between metabolic syndrome and disease activity in rheumatoid arthritis. *Sci World J* 11:1195–1205
- Lee SG, Kim JM, Lee SH, Kim KH, Kim JH et al (2013) Is the frequency of metabolic syndrome higher in South Korean women with rheumatoid arthritis than in healthy subjects? *Korean J Intern Med* 28:206–215
- Puenpatom RA, Victor TW (2009) Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. *Postgrad Med* 121:9–20
- Leite AA, Costa AJ, Lima Bde A, Padilha AV, Albuquerque EC, Marques CD (2011) Comorbidities in patients with osteoarthritis: frequency and impact on pain and physical function. *Rev Bras Reumatol* 51:118–123
- Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T (2011) Association of knee osteoarthritis with the accumulation of metabolic risk factors such as overweight, hypertension, dyslipidemia, and impaired glucose tolerance in Japanese men and women: the ROAD study. *J Rheumatol* 38:921–930
- Carman WJ, Sowers M, Hawthorne VM, Weissfeld LA (1994) Obesity as a risk factor for osteoarthritis of the hand and wrist: a prospective study. *Am J Epidemiol* 139:119–129
- Velasquez MT, Katz JD (2010) Osteoarthritis: another component of metabolic syndrome? *Metab Syndr Relat Disord* 8:295–305
- Sowers M, Jannausch M, Stein E, Jamadar D, Hochberg M, Lachance L (2002) C-reactive protein as a biomarker of emergent osteoarthritis. *Osteoarthr Cartil* 10:595–601
- Roberson LL, Aneni EC, Maziak W et al (2014) Beyond BMI: the ‘metabolically & healthy obese’ phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality—a systematic review. *BMC Public Health* 14:14
- Dessein PH, Stanwix AE, Joffe BI (2002) Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. *Arthritis Res* 4:R5

27. Erb N, Pace AV, Douglas KMJ, Banks MJ, Kitas GD (2004) Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. *Scand J Rheumat* 33:293–299
28. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 31:315–324
29. Altman R, Alarcon G, Appelrouth D, Bloch D et al (1991) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. *Arthritis Rheum* 34:505–514
30. Altman R, Alarcon G, Appelrouth D, Bloch D et al (1990) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. *Arthritis Rheum* 33:1601–1610
31. Altman R, Asch E, Bloch D et al (1986) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. *Arthritis Rheum* 29:1039–1049
32. See R, Abdullah SM, McGuire DK et al (2007) The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study. *J Am Coll Cardiol* 50:752–759
33. Mannion AF, Balague F, Pellise F, Cedraschi C (2007) Pain measurement in patients with low back pain. *Nat Clin Pract Rheumatol* 3:610–618
34. The DAS calculator. <http://www.das-score.nl/dascalators.html>. Accessed 21 March 2011
35. Kirwan JR, Reeback JS (1986) Stanford health assessment questionnaire modified to assess disability in British patients with rheumatoid arthritis. *Br J Rheumatol* 25:206–209
36. Mancia G, De Backer G, Dominiczak A et al (2007) Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 28:1462–1536
37. World Health Organization. Department of Noncommunicable Disease Surveillance (1999) Definition and diagnostic criteria for diabetes mellitus and other categories of glucose intolerance. In: Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. World Health Organization, Geneva, pp 2–8
38. Zhang J, Yu KF (1998) What's the relative risk? *JAMA* 280:1690–1691
39. Ivezic-Lalic D, Bergman Markovic B, Kranjcevic K, Kern J, Vrdoljak D, Vucak J (2013) Diversity of metabolic syndrome criteria in association with cardiovascular diseases—a family medicine-based investigation. *Med Sci Monit* 19:571–578
40. Shahin D, Eltoraby E, Mesbah A, Houssen M (2010) Insulin resistance in early untreated rheumatoid arthritis patients. *Clin Biochem* 43:661–665
41. Karakoc M, Batmaz I, Sariyildiz MA, Tahtasiz M, Cevik R et al (2012) The relationship of metabolic syndrome with disease activity and the functional status in patients with rheumatoid arthritis. *Clin Med Res* 4(4):279–285
42. Abourazzak FE, Mansouri S, Najdi A, Tahiri L, Nejari C, Harzy T (2014) Prevalence of metabolic syndrome in patients with rheumatoid arthritis in Morocco: a cross-sectional study of 179 cases. *Clin Rheumatol* 33:1549–1555
43. Sellam J, Berenbaum F (2013) Is osteoarthritis a metabolic disease? *Joint Bone Spine* 80:568–573
44. Zhuo Q, Yang W, Chen J, Wang Y (2012) Metabolic syndrome meets osteoarthritis. *Nat Rev Rheumatol* 8:729–737
45. Kornaat PR, Sharma R, van der Geest RJ et al (2009) Positive association between increased popliteal artery vessel wall thickness and generalized osteoarthritis: is OA also part of the metabolic syndrome? *Skeletal Radiol* 38:1147
46. Karvonen-Gutierrez CA, Sowers MR, Heeringa SG (2012) Sex dimorphism in the association of cardiometabolic characteristics and osteophytes-defined radiographic knee osteoarthritis among obese and non-obese adults: NHANES III. *Osteoarthr Cartil* 20:614–621
47. Yoshimura N, Muraki S, Oka H et al (2012) Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. *Osteoarthr Cartil* 20:1217–1226
48. Frey MI, Barrett-Conner E, Sledge PA et al (1996) The effect of noninsulin dependent diabetes on the prevalence of clinical osteoarthritis. A population based study. *J Rheumatol* 23:716–722
49. Anderson JJ, Felson DT (1988) Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I). Evidence for an association with overweight, race, and physical demands of work. *Am J Epidemiol* 128:179–189
50. Morovic-Vergles J, Salamon L, Marasovic-Krstulovic D, Kehler T, Sakic D, Badovinac O, Vlaskovic T et al (2013) Is the prevalence of arterial hypertension in rheumatoid arthritis and osteoarthritis associated with disease? *Rheumatol Int* 33:1185–1192